Y-Biologics, Inc. (KOSDAQ:338840)
9,050.00
+200.00 (2.26%)
At close: Sep 9, 2026
Y-Biologics Revenue
Y-Biologics had revenue of 1.55B KRW in the quarter ending June 30, 2026, with 32.85% growth. This brings the company's revenue in the last twelve months to 3.17B, down -46.81% year-over-year. In the year 2025, Y-Biologics had annual revenue of 2.91B, down -49.45%.
Revenue (ttm)
3.17B
Revenue Growth
-46.81%
P/S Ratio
43.87
Revenue / Employee
n/a
Employees
n/a
Market Cap
139.07B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.91B | -2.85B | -49.45% |
| Dec 31, 2024 | 5.76B | 2.28B | 65.64% |
| Dec 31, 2023 | 3.48B | -671.48M | -16.18% |
| Dec 31, 2022 | 4.15B | -696.78M | -14.37% |
| Dec 31, 2021 | 4.85B | -1.88B | -27.99% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cell Biotech | 60.40B |
| ISU Abxis | 51.04B |
| Genome & Company | 24.46B |
| NIBEC | 22.60B |
| CORESTEMCHEMON | 18.29B |
| Prestige Biologics | 18.03B |
| Bio Solution | 17.39B |
| TiumBio | 15.00B |